Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 0.5 mg/mL, 2.5 mg/mL) |
Drug Class | Vasoconstrictors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to increase blood pressure in adults with septic or other distributive shock.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Angiotensin II (Giapreza) is a potent vasoconstrictor used to manage hypotension, particularly in adults with septic or other distributive shocks where traditional vasopressors have failed or are required in high doses.
- Five systematic reviews/meta-analyses were reviewed for this analysis.
- Angiotensin II has been found to significantly increase mean arterial pressure (MAP) when compared to catecholamine vasopressors such as norepinephrine, epinephrine, and phenylephrine, potentially reducing the dose required of these traditional vasopressors.
- Safety concerns associated with all vasopressors including angiotensin II were noted across the documents; specifically, thromboembolism was identified as a safety concern for angiotensin II, while catecholamine vasopressors have been linked with splanchnic vasoconstriction and resultant hypoperfusion.
- In specific population usage scenarios where initial treatments like norepinephrine have proven insufficient or ineffective, angiotensin II could be considered a third-line treatment option, according to one study on outcomes related to vasodilatory shock.
- Mortality rates among patients administered with angiotensin II were notably lower in those who had elevated renin levels, indicating that it might be particularly effective within this subgroup.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Giapreza (angiotensin II) Prescribing Information. | 2021 | La Jolla Pharmaceutical Company., San Diego, CA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
How effective is angiotensin II in decreasing mortality of vasodilatory shock? a systematic review. | 2023 | Open Access Emergency Medicine |
Treatment strategies for clozapine-induced hypotension: a systematic review. | 2022 | Therapeutic Advances in Psychopharmacology |
Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis. | 2022 | The American Journal of Emergency Medicine |
Novel vasopressors in the treatment of vasodilatory shock: a systematic review of angiotensin ii, selepressin, and terlipressin. | 2020 | Journal of Intensive Care Medicine |
Angiotensin II: a new vasopressor for the treatment of distributive shock. | 2019 | Clinical Therapeutics |